Metalloproteinases in the pathogenesis and progression of metabolic syndrome: potential targets for improved outcomes Article Swipe
Gabriela Berg
,
Verónica Miksztowicz
·
YOU?
·
· 2015
· Open Access
·
· DOI: https://doi.org/10.2147/mnm.s88993
YOU?
·
· 2015
· Open Access
·
· DOI: https://doi.org/10.2147/mnm.s88993
Matrix metalloproteinases (MMPs) constitute a family of more than 25 calcium-dependent, zinc-containing endopeptidases, synthesized by multiple cell types. These enzymes play an important role during physiological tissue development and remodeling and angiogenesis, as well as in pathophysiological conditions such as obesity and atherosclerotic process. Moreover, circulating levels of MMPs have emerged as potential biomarkers of cardiovascular disease. MMPs are regulated by different factors such as insulin resistance and obesity. Different components of the metabolic syndrome have been identified as possible stimulus for the synthesis and activity of MMPs. On the other hand, pro-inflammatory and anti-inflammatory cytokines, such as leptin and adiponectin, respectively, are associated with the regulation of MMPs. Leptin induces expression of MMP-2 activators as well as expression of MMP-2, MMP-9, and tissue inhibitor of metalloproteinase (TIMP)-1 in different human cells. Adiponectin may play a protective role in plaque rupture through selectively increasing TIMP expression. The hepatic manifestation of metabolic syndrome is nonalcoholic fatty liver disease (NAFLD). MMPs may remodel the liver parenchyma during the process of liver fibrosis. MMP-2 and MT1-MMP have been considered to be fibrogenic enzymes.There are few studies analyzing the role of MMPs in NAFLD, and most of them include study on mRNA expression, but even the results on their expression pattern remains controversial. MMPs could be considered as possible therapeutic targets. Different studies demonstrated that metformin, thiazolidinediones, and antibiotics could have inhibitory effects on the expression of MMPs; however, a rational study of lifestyle modifications as well as further studies of pharmacological therapies that influence MMPs are necessary to generate the information that physicians will probably need to improve the treatment of patients. The aim of this revision is to update the data about MMPs in the pathogenesis and progression of metabolic syndrome and the possible effect of different drugs on the behavior of these enzymes. Keywords: metalloproteinases, metabolic syndrome, insulin resistance, nonalcoholic fatty liver, metformin, thiazolidinediones
Related Topics
Concepts
Matrix metalloproteinase
Adiponectin
Nonalcoholic fatty liver disease
Angiogenesis
Endocrinology
Medicine
Metabolic syndrome
Fibrosis
Internal medicine
Insulin resistance
Cancer research
Biology
Fatty liver
Disease
Insulin
Diabetes mellitus
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.2147/mnm.s88993
- https://www.dovepress.com/getfile.php?fileID=27665
- OA Status
- diamond
- Cited By
- 11
- References
- 105
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W1809619553
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W1809619553Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.2147/mnm.s88993Digital Object Identifier
- Title
-
Metalloproteinases in the pathogenesis and progression of metabolic syndrome: potential targets for improved outcomesWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2015Year of publication
- Publication date
-
2015-10-01Full publication date if available
- Authors
-
Gabriela Berg, Verónica MiksztowiczList of authors in order
- Landing page
-
https://doi.org/10.2147/mnm.s88993Publisher landing page
- PDF URL
-
https://www.dovepress.com/getfile.php?fileID=27665Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
diamondOpen access status per OpenAlex
- OA URL
-
https://www.dovepress.com/getfile.php?fileID=27665Direct OA link when available
- Concepts
-
Matrix metalloproteinase, Adiponectin, Nonalcoholic fatty liver disease, Angiogenesis, Endocrinology, Medicine, Metabolic syndrome, Fibrosis, Internal medicine, Insulin resistance, Cancer research, Biology, Fatty liver, Disease, Insulin, Diabetes mellitusTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
11Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1, 2024: 2, 2023: 1, 2022: 3, 2019: 3Per-year citation counts (last 5 years)
- References (count)
-
105Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W1809619553 |
|---|---|
| doi | https://doi.org/10.2147/mnm.s88993 |
| ids.doi | https://doi.org/10.2147/mnm.s88993 |
| ids.mag | 1809619553 |
| ids.openalex | https://openalex.org/W1809619553 |
| fwci | 0.23836718 |
| type | article |
| title | Metalloproteinases in the pathogenesis and progression of metabolic syndrome: potential targets for improved outcomes |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | 51 |
| biblio.first_page | 51 |
| topics[0].id | https://openalex.org/T10528 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9979000091552734 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2713 |
| topics[0].subfield.display_name | Epidemiology |
| topics[0].display_name | Adipokines, Inflammation, and Metabolic Diseases |
| topics[1].id | https://openalex.org/T10620 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.995199978351593 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1306 |
| topics[1].subfield.display_name | Cancer Research |
| topics[1].display_name | Protease and Inhibitor Mechanisms |
| topics[2].id | https://openalex.org/T10394 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9830999970436096 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2746 |
| topics[2].subfield.display_name | Surgery |
| topics[2].display_name | Lipoproteins and Cardiovascular Health |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C109523444 |
| concepts[0].level | 2 |
| concepts[0].score | 0.8734403848648071 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q424216 |
| concepts[0].display_name | Matrix metalloproteinase |
| concepts[1].id | https://openalex.org/C2776782570 |
| concepts[1].level | 4 |
| concepts[1].score | 0.6586669087409973 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q357439 |
| concepts[1].display_name | Adiponectin |
| concepts[2].id | https://openalex.org/C2776954865 |
| concepts[2].level | 4 |
| concepts[2].score | 0.6474745869636536 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q1546498 |
| concepts[2].display_name | Nonalcoholic fatty liver disease |
| concepts[3].id | https://openalex.org/C2780394083 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5869358777999878 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q539568 |
| concepts[3].display_name | Angiogenesis |
| concepts[4].id | https://openalex.org/C134018914 |
| concepts[4].level | 1 |
| concepts[4].score | 0.45750048756599426 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q162606 |
| concepts[4].display_name | Endocrinology |
| concepts[5].id | https://openalex.org/C71924100 |
| concepts[5].level | 0 |
| concepts[5].score | 0.4378044903278351 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[5].display_name | Medicine |
| concepts[6].id | https://openalex.org/C2780578515 |
| concepts[6].level | 3 |
| concepts[6].score | 0.4287562966346741 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q657193 |
| concepts[6].display_name | Metabolic syndrome |
| concepts[7].id | https://openalex.org/C2780559512 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4184260666370392 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q605709 |
| concepts[7].display_name | Fibrosis |
| concepts[8].id | https://openalex.org/C126322002 |
| concepts[8].level | 1 |
| concepts[8].score | 0.41810932755470276 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[8].display_name | Internal medicine |
| concepts[9].id | https://openalex.org/C2777391703 |
| concepts[9].level | 3 |
| concepts[9].score | 0.4133293628692627 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q1053470 |
| concepts[9].display_name | Insulin resistance |
| concepts[10].id | https://openalex.org/C502942594 |
| concepts[10].level | 1 |
| concepts[10].score | 0.39799439907073975 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[10].display_name | Cancer research |
| concepts[11].id | https://openalex.org/C86803240 |
| concepts[11].level | 0 |
| concepts[11].score | 0.38955244421958923 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[11].display_name | Biology |
| concepts[12].id | https://openalex.org/C2778772119 |
| concepts[12].level | 3 |
| concepts[12].score | 0.2916707992553711 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q6058862 |
| concepts[12].display_name | Fatty liver |
| concepts[13].id | https://openalex.org/C2779134260 |
| concepts[13].level | 2 |
| concepts[13].score | 0.24739551544189453 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[13].display_name | Disease |
| concepts[14].id | https://openalex.org/C2779306644 |
| concepts[14].level | 2 |
| concepts[14].score | 0.17005914449691772 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q2002370 |
| concepts[14].display_name | Insulin |
| concepts[15].id | https://openalex.org/C555293320 |
| concepts[15].level | 2 |
| concepts[15].score | 0.16558241844177246 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q12206 |
| concepts[15].display_name | Diabetes mellitus |
| keywords[0].id | https://openalex.org/keywords/matrix-metalloproteinase |
| keywords[0].score | 0.8734403848648071 |
| keywords[0].display_name | Matrix metalloproteinase |
| keywords[1].id | https://openalex.org/keywords/adiponectin |
| keywords[1].score | 0.6586669087409973 |
| keywords[1].display_name | Adiponectin |
| keywords[2].id | https://openalex.org/keywords/nonalcoholic-fatty-liver-disease |
| keywords[2].score | 0.6474745869636536 |
| keywords[2].display_name | Nonalcoholic fatty liver disease |
| keywords[3].id | https://openalex.org/keywords/angiogenesis |
| keywords[3].score | 0.5869358777999878 |
| keywords[3].display_name | Angiogenesis |
| keywords[4].id | https://openalex.org/keywords/endocrinology |
| keywords[4].score | 0.45750048756599426 |
| keywords[4].display_name | Endocrinology |
| keywords[5].id | https://openalex.org/keywords/medicine |
| keywords[5].score | 0.4378044903278351 |
| keywords[5].display_name | Medicine |
| keywords[6].id | https://openalex.org/keywords/metabolic-syndrome |
| keywords[6].score | 0.4287562966346741 |
| keywords[6].display_name | Metabolic syndrome |
| keywords[7].id | https://openalex.org/keywords/fibrosis |
| keywords[7].score | 0.4184260666370392 |
| keywords[7].display_name | Fibrosis |
| keywords[8].id | https://openalex.org/keywords/internal-medicine |
| keywords[8].score | 0.41810932755470276 |
| keywords[8].display_name | Internal medicine |
| keywords[9].id | https://openalex.org/keywords/insulin-resistance |
| keywords[9].score | 0.4133293628692627 |
| keywords[9].display_name | Insulin resistance |
| keywords[10].id | https://openalex.org/keywords/cancer-research |
| keywords[10].score | 0.39799439907073975 |
| keywords[10].display_name | Cancer research |
| keywords[11].id | https://openalex.org/keywords/biology |
| keywords[11].score | 0.38955244421958923 |
| keywords[11].display_name | Biology |
| keywords[12].id | https://openalex.org/keywords/fatty-liver |
| keywords[12].score | 0.2916707992553711 |
| keywords[12].display_name | Fatty liver |
| keywords[13].id | https://openalex.org/keywords/disease |
| keywords[13].score | 0.24739551544189453 |
| keywords[13].display_name | Disease |
| keywords[14].id | https://openalex.org/keywords/insulin |
| keywords[14].score | 0.17005914449691772 |
| keywords[14].display_name | Insulin |
| keywords[15].id | https://openalex.org/keywords/diabetes-mellitus |
| keywords[15].score | 0.16558241844177246 |
| keywords[15].display_name | Diabetes mellitus |
| language | en |
| locations[0].id | doi:10.2147/mnm.s88993 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210230208 |
| locations[0].source.issn | 2324-2027 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2324-2027 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Metalloproteinases In Medicine |
| locations[0].source.host_organization | https://openalex.org/P4310320348 |
| locations[0].source.host_organization_name | Dove Medical Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320348 |
| locations[0].license | other-oa |
| locations[0].pdf_url | https://www.dovepress.com/getfile.php?fileID=27665 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/other-oa |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Metalloproteinases In Medicine |
| locations[0].landing_page_url | https://doi.org/10.2147/mnm.s88993 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5053343152 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-5787-8960 |
| authorships[0].author.display_name | Gabriela Berg |
| authorships[0].countries | AR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I24354313 |
| authorships[0].affiliations[0].raw_affiliation_string | Lipids and Atherosclerosis Laboratory, Department of Clinical Biochemistry, Faculty of Pharmacy and Biochemistry, INFIBIOC, University of Buenos Aires, Buenos Aires, Argentina |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I4210152303 |
| authorships[0].affiliations[1].raw_affiliation_string | National Scientific and Technical Research Council (CONICET), Mendoza, Argentina |
| authorships[0].institutions[0].id | https://openalex.org/I4210152303 |
| authorships[0].institutions[0].ror | https://ror.org/055wmc747 |
| authorships[0].institutions[0].type | facility |
| authorships[0].institutions[0].lineage | https://openalex.org/I151201029, https://openalex.org/I4210123736, https://openalex.org/I4210152303, https://openalex.org/I4387155568 |
| authorships[0].institutions[0].country_code | AR |
| authorships[0].institutions[0].display_name | Centro Científico Tecnológico - Mendoza |
| authorships[0].institutions[1].id | https://openalex.org/I24354313 |
| authorships[0].institutions[1].ror | https://ror.org/0081fs513 |
| authorships[0].institutions[1].type | education |
| authorships[0].institutions[1].lineage | https://openalex.org/I24354313 |
| authorships[0].institutions[1].country_code | AR |
| authorships[0].institutions[1].display_name | Universidad de Buenos Aires |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Gabriela Berg |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Lipids and Atherosclerosis Laboratory, Department of Clinical Biochemistry, Faculty of Pharmacy and Biochemistry, INFIBIOC, University of Buenos Aires, Buenos Aires, Argentina, National Scientific and Technical Research Council (CONICET), Mendoza, Argentina |
| authorships[1].author.id | https://openalex.org/A5065106283 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-2104-8495 |
| authorships[1].author.display_name | Verónica Miksztowicz |
| authorships[1].countries | AR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I24354313 |
| authorships[1].affiliations[0].raw_affiliation_string | Lipids and Atherosclerosis Laboratory, Department of Clinical Biochemistry, Faculty of Pharmacy and Biochemistry, INFIBIOC, University of Buenos Aires, Buenos Aires, Argentina |
| authorships[1].affiliations[1].institution_ids | https://openalex.org/I4210152303 |
| authorships[1].affiliations[1].raw_affiliation_string | National Scientific and Technical Research Council (CONICET), Mendoza, Argentina |
| authorships[1].institutions[0].id | https://openalex.org/I4210152303 |
| authorships[1].institutions[0].ror | https://ror.org/055wmc747 |
| authorships[1].institutions[0].type | facility |
| authorships[1].institutions[0].lineage | https://openalex.org/I151201029, https://openalex.org/I4210123736, https://openalex.org/I4210152303, https://openalex.org/I4387155568 |
| authorships[1].institutions[0].country_code | AR |
| authorships[1].institutions[0].display_name | Centro Científico Tecnológico - Mendoza |
| authorships[1].institutions[1].id | https://openalex.org/I24354313 |
| authorships[1].institutions[1].ror | https://ror.org/0081fs513 |
| authorships[1].institutions[1].type | education |
| authorships[1].institutions[1].lineage | https://openalex.org/I24354313 |
| authorships[1].institutions[1].country_code | AR |
| authorships[1].institutions[1].display_name | Universidad de Buenos Aires |
| authorships[1].author_position | last |
| authorships[1].raw_author_name | Veronica Miksztowicz |
| authorships[1].is_corresponding | True |
| authorships[1].raw_affiliation_strings | Lipids and Atherosclerosis Laboratory, Department of Clinical Biochemistry, Faculty of Pharmacy and Biochemistry, INFIBIOC, University of Buenos Aires, Buenos Aires, Argentina, National Scientific and Technical Research Council (CONICET), Mendoza, Argentina |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.dovepress.com/getfile.php?fileID=27665 |
| open_access.oa_status | diamond |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Metalloproteinases in the pathogenesis and progression of metabolic syndrome: potential targets for improved outcomes |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10528 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9979000091552734 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2713 |
| primary_topic.subfield.display_name | Epidemiology |
| primary_topic.display_name | Adipokines, Inflammation, and Metabolic Diseases |
| related_works | https://openalex.org/W2098541345, https://openalex.org/W4206431747, https://openalex.org/W2066961600, https://openalex.org/W3011060600, https://openalex.org/W1964989449, https://openalex.org/W2368901059, https://openalex.org/W2507601459, https://openalex.org/W2385089255, https://openalex.org/W4214910348, https://openalex.org/W2115223685 |
| cited_by_count | 11 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 2 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 1 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 3 |
| counts_by_year[4].year | 2019 |
| counts_by_year[4].cited_by_count | 3 |
| counts_by_year[5].year | 2018 |
| counts_by_year[5].cited_by_count | 1 |
| locations_count | 1 |
| best_oa_location.id | doi:10.2147/mnm.s88993 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210230208 |
| best_oa_location.source.issn | 2324-2027 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2324-2027 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Metalloproteinases In Medicine |
| best_oa_location.source.host_organization | https://openalex.org/P4310320348 |
| best_oa_location.source.host_organization_name | Dove Medical Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320348 |
| best_oa_location.license | other-oa |
| best_oa_location.pdf_url | https://www.dovepress.com/getfile.php?fileID=27665 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/other-oa |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Metalloproteinases In Medicine |
| best_oa_location.landing_page_url | https://doi.org/10.2147/mnm.s88993 |
| primary_location.id | doi:10.2147/mnm.s88993 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210230208 |
| primary_location.source.issn | 2324-2027 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2324-2027 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Metalloproteinases In Medicine |
| primary_location.source.host_organization | https://openalex.org/P4310320348 |
| primary_location.source.host_organization_name | Dove Medical Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320348 |
| primary_location.license | other-oa |
| primary_location.pdf_url | https://www.dovepress.com/getfile.php?fileID=27665 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/other-oa |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Metalloproteinases In Medicine |
| primary_location.landing_page_url | https://doi.org/10.2147/mnm.s88993 |
| publication_date | 2015-10-01 |
| publication_year | 2015 |
| referenced_works | https://openalex.org/W2049569075, https://openalex.org/W2125930919, https://openalex.org/W2156682146, https://openalex.org/W2160969448, https://openalex.org/W1598846876, https://openalex.org/W2106343349, https://openalex.org/W7075606806, https://openalex.org/W2029910413, https://openalex.org/W2169729175, https://openalex.org/W2112476800, https://openalex.org/W2036414307, https://openalex.org/W2136858036, https://openalex.org/W2171032788, https://openalex.org/W2123211548, https://openalex.org/W1895025635, https://openalex.org/W2337133379, https://openalex.org/W2047431499, https://openalex.org/W1985497859, https://openalex.org/W2073814753, https://openalex.org/W1990692512, https://openalex.org/W2127610524, https://openalex.org/W2153366902, https://openalex.org/W2127767818, https://openalex.org/W2110871895, https://openalex.org/W2086487286, https://openalex.org/W3155759454, https://openalex.org/W2042061429, https://openalex.org/W2000588886, https://openalex.org/W2047257800, https://openalex.org/W1971826130, https://openalex.org/W2060471083, https://openalex.org/W2111840256, https://openalex.org/W6657024610, https://openalex.org/W6645366739, https://openalex.org/W2037187996, https://openalex.org/W1976304160, https://openalex.org/W1967666737, https://openalex.org/W2361100796, https://openalex.org/W6673604130, https://openalex.org/W6655305429, https://openalex.org/W2122431684, https://openalex.org/W1541004533, https://openalex.org/W2050341047, https://openalex.org/W2107732097, https://openalex.org/W2042896784, https://openalex.org/W2152487395, https://openalex.org/W2101706129, https://openalex.org/W2114524401, https://openalex.org/W1971094896, https://openalex.org/W2015965303, https://openalex.org/W2017757888, https://openalex.org/W4236093478, https://openalex.org/W2146845495, https://openalex.org/W2155351009, https://openalex.org/W2151440732, https://openalex.org/W2320099395, https://openalex.org/W2357212040, https://openalex.org/W2038578511, https://openalex.org/W2169392458, https://openalex.org/W2002771508, https://openalex.org/W2126910504, https://openalex.org/W2021170188, https://openalex.org/W1574875639, https://openalex.org/W2151222320, https://openalex.org/W2020079510, https://openalex.org/W2060229969, https://openalex.org/W2121311096, https://openalex.org/W2116590039, https://openalex.org/W2033389820, https://openalex.org/W2115408133, https://openalex.org/W2121948800, https://openalex.org/W4240735590, https://openalex.org/W2015835353, https://openalex.org/W2074280336, https://openalex.org/W2026967508, https://openalex.org/W2157559566, https://openalex.org/W2110266682, https://openalex.org/W2166673123, https://openalex.org/W4252826925, https://openalex.org/W2093035330, https://openalex.org/W2101630029, https://openalex.org/W2290700786, https://openalex.org/W2126744763, https://openalex.org/W2145434394, https://openalex.org/W2125080519, https://openalex.org/W1971653265, https://openalex.org/W2135124706, https://openalex.org/W2323637528, https://openalex.org/W1552424392, https://openalex.org/W2001787555, https://openalex.org/W2010430993, https://openalex.org/W2024605566, https://openalex.org/W2065745631, https://openalex.org/W2129373188, https://openalex.org/W2018000856, https://openalex.org/W2056490176, https://openalex.org/W4232051691, https://openalex.org/W2152646491, https://openalex.org/W2159284697, https://openalex.org/W2113630000, https://openalex.org/W1525305507, https://openalex.org/W2156370651, https://openalex.org/W175031653, https://openalex.org/W2143104968, https://openalex.org/W2058599631 |
| referenced_works_count | 105 |
| abstract_inverted_index.a | 5, 136, 236 |
| abstract_inverted_index.25 | 10 |
| abstract_inverted_index.On | 89 |
| abstract_inverted_index.an | 22 |
| abstract_inverted_index.as | 33, 35, 40, 52, 65, 79, 98, 116, 118, 214, 242, 244 |
| abstract_inverted_index.be | 178, 212 |
| abstract_inverted_index.by | 15, 61 |
| abstract_inverted_index.in | 36, 129, 139, 189, 282 |
| abstract_inverted_index.is | 153, 275 |
| abstract_inverted_index.of | 7, 48, 55, 72, 87, 108, 113, 120, 126, 150, 168, 187, 193, 233, 239, 247, 268, 272, 287, 294, 300 |
| abstract_inverted_index.on | 197, 204, 230, 297 |
| abstract_inverted_index.to | 177, 255, 264, 276 |
| abstract_inverted_index.The | 147, 270 |
| abstract_inverted_index.aim | 271 |
| abstract_inverted_index.and | 29, 31, 42, 68, 85, 94, 100, 123, 172, 191, 224, 285, 290 |
| abstract_inverted_index.are | 59, 103, 181, 253 |
| abstract_inverted_index.but | 200 |
| abstract_inverted_index.few | 182 |
| abstract_inverted_index.for | 82 |
| abstract_inverted_index.may | 134, 160 |
| abstract_inverted_index.the | 73, 83, 90, 106, 162, 166, 185, 202, 231, 257, 266, 278, 283, 291, 298 |
| abstract_inverted_index.MMPs | 49, 58, 159, 188, 210, 252, 281 |
| abstract_inverted_index.TIMP | 145 |
| abstract_inverted_index.been | 77, 175 |
| abstract_inverted_index.cell | 17 |
| abstract_inverted_index.data | 279 |
| abstract_inverted_index.even | 201 |
| abstract_inverted_index.have | 50, 76, 174, 227 |
| abstract_inverted_index.mRNA | 198 |
| abstract_inverted_index.more | 8 |
| abstract_inverted_index.most | 192 |
| abstract_inverted_index.need | 263 |
| abstract_inverted_index.play | 21, 135 |
| abstract_inverted_index.role | 24, 138, 186 |
| abstract_inverted_index.such | 39, 64, 97 |
| abstract_inverted_index.than | 9 |
| abstract_inverted_index.that | 221, 250, 259 |
| abstract_inverted_index.them | 194 |
| abstract_inverted_index.this | 273 |
| abstract_inverted_index.well | 34, 117, 243 |
| abstract_inverted_index.will | 261 |
| abstract_inverted_index.with | 105 |
| abstract_inverted_index.MMP-2 | 114, 171 |
| abstract_inverted_index.MMPs. | 88, 109 |
| abstract_inverted_index.MMPs; | 234 |
| abstract_inverted_index.These | 19 |
| abstract_inverted_index.about | 280 |
| abstract_inverted_index.could | 211, 226 |
| abstract_inverted_index.drugs | 296 |
| abstract_inverted_index.fatty | 155, 310 |
| abstract_inverted_index.hand, | 92 |
| abstract_inverted_index.human | 131 |
| abstract_inverted_index.liver | 156, 163, 169 |
| abstract_inverted_index.other | 91 |
| abstract_inverted_index.study | 196, 238 |
| abstract_inverted_index.their | 205 |
| abstract_inverted_index.these | 301 |
| abstract_inverted_index.(MMPs) | 3 |
| abstract_inverted_index.Leptin | 110 |
| abstract_inverted_index.MMP-2, | 121 |
| abstract_inverted_index.MMP-9, | 122 |
| abstract_inverted_index.Matrix | 1 |
| abstract_inverted_index.NAFLD, | 190 |
| abstract_inverted_index.cells. | 132 |
| abstract_inverted_index.during | 25, 165 |
| abstract_inverted_index.effect | 293 |
| abstract_inverted_index.family | 6 |
| abstract_inverted_index.leptin | 99 |
| abstract_inverted_index.levels | 47 |
| abstract_inverted_index.liver, | 311 |
| abstract_inverted_index.plaque | 140 |
| abstract_inverted_index.tissue | 27, 124 |
| abstract_inverted_index.types. | 18 |
| abstract_inverted_index.update | 277 |
| abstract_inverted_index.MT1-MMP | 173 |
| abstract_inverted_index.disease | 157 |
| abstract_inverted_index.effects | 229 |
| abstract_inverted_index.emerged | 51 |
| abstract_inverted_index.enzymes | 20 |
| abstract_inverted_index.factors | 63 |
| abstract_inverted_index.further | 245 |
| abstract_inverted_index.hepatic | 148 |
| abstract_inverted_index.improve | 265 |
| abstract_inverted_index.include | 195 |
| abstract_inverted_index.induces | 111 |
| abstract_inverted_index.insulin | 66, 307 |
| abstract_inverted_index.obesity | 41 |
| abstract_inverted_index.pattern | 207 |
| abstract_inverted_index.process | 167 |
| abstract_inverted_index.remains | 208 |
| abstract_inverted_index.remodel | 161 |
| abstract_inverted_index.results | 203 |
| abstract_inverted_index.rupture | 141 |
| abstract_inverted_index.studies | 183, 219, 246 |
| abstract_inverted_index.through | 142 |
| abstract_inverted_index.(NAFLD). | 158 |
| abstract_inverted_index.(TIMP)-1 | 128 |
| abstract_inverted_index.activity | 86 |
| abstract_inverted_index.behavior | 299 |
| abstract_inverted_index.disease. | 57 |
| abstract_inverted_index.enzymes. | 302 |
| abstract_inverted_index.generate | 256 |
| abstract_inverted_index.however, | 235 |
| abstract_inverted_index.multiple | 16 |
| abstract_inverted_index.obesity. | 69 |
| abstract_inverted_index.possible | 80, 215, 292 |
| abstract_inverted_index.probably | 262 |
| abstract_inverted_index.process. | 44 |
| abstract_inverted_index.rational | 237 |
| abstract_inverted_index.revision | 274 |
| abstract_inverted_index.stimulus | 81 |
| abstract_inverted_index.syndrome | 75, 152, 289 |
| abstract_inverted_index.targets. | 217 |
| abstract_inverted_index.Abstract: | 0 |
| abstract_inverted_index.Different | 70, 218 |
| abstract_inverted_index.Keywords: | 303 |
| abstract_inverted_index.Moreover, | 45 |
| abstract_inverted_index.analyzing | 184 |
| abstract_inverted_index.different | 62, 130, 295 |
| abstract_inverted_index.fibrosis. | 170 |
| abstract_inverted_index.important | 23 |
| abstract_inverted_index.influence | 251 |
| abstract_inverted_index.inhibitor | 125 |
| abstract_inverted_index.lifestyle | 240 |
| abstract_inverted_index.metabolic | 74, 151, 288, 305 |
| abstract_inverted_index.necessary | 254 |
| abstract_inverted_index.patients. | 269 |
| abstract_inverted_index.potential | 53 |
| abstract_inverted_index.regulated | 60 |
| abstract_inverted_index.syndrome, | 306 |
| abstract_inverted_index.synthesis | 84 |
| abstract_inverted_index.therapies | 249 |
| abstract_inverted_index.treatment | 267 |
| abstract_inverted_index.activators | 115 |
| abstract_inverted_index.associated | 104 |
| abstract_inverted_index.biomarkers | 54 |
| abstract_inverted_index.components | 71 |
| abstract_inverted_index.conditions | 38 |
| abstract_inverted_index.considered | 176, 213 |
| abstract_inverted_index.constitute | 4 |
| abstract_inverted_index.cytokines, | 96 |
| abstract_inverted_index.expression | 112, 119, 206, 232 |
| abstract_inverted_index.fibrogenic | 179 |
| abstract_inverted_index.identified | 78 |
| abstract_inverted_index.increasing | 144 |
| abstract_inverted_index.inhibitory | 228 |
| abstract_inverted_index.metformin, | 222, 312 |
| abstract_inverted_index.parenchyma | 164 |
| abstract_inverted_index.physicians | 260 |
| abstract_inverted_index.protective | 137 |
| abstract_inverted_index.regulation | 107 |
| abstract_inverted_index.remodeling | 30 |
| abstract_inverted_index.resistance | 67 |
| abstract_inverted_index.Adiponectin | 133 |
| abstract_inverted_index.antibiotics | 225 |
| abstract_inverted_index.circulating | 46 |
| abstract_inverted_index.development | 28 |
| abstract_inverted_index.expression, | 199 |
| abstract_inverted_index.expression. | 146 |
| abstract_inverted_index.information | 258 |
| abstract_inverted_index.progression | 286 |
| abstract_inverted_index.resistance, | 308 |
| abstract_inverted_index.selectively | 143 |
| abstract_inverted_index.synthesized | 14 |
| abstract_inverted_index.therapeutic | 216 |
| abstract_inverted_index.adiponectin, | 101 |
| abstract_inverted_index.demonstrated | 220 |
| abstract_inverted_index.nonalcoholic | 154, 309 |
| abstract_inverted_index.pathogenesis | 284 |
| abstract_inverted_index.angiogenesis, | 32 |
| abstract_inverted_index.enzymes.There | 180 |
| abstract_inverted_index.manifestation | 149 |
| abstract_inverted_index.modifications | 241 |
| abstract_inverted_index.physiological | 26 |
| abstract_inverted_index.respectively, | 102 |
| abstract_inverted_index.cardiovascular | 56 |
| abstract_inverted_index.controversial. | 209 |
| abstract_inverted_index.atherosclerotic | 43 |
| abstract_inverted_index.endopeptidases, | 13 |
| abstract_inverted_index.pharmacological | 248 |
| abstract_inverted_index.zinc-containing | 12 |
| abstract_inverted_index.pro-inflammatory | 93 |
| abstract_inverted_index.anti-inflammatory | 95 |
| abstract_inverted_index.metalloproteinase | 127 |
| abstract_inverted_index.calcium-dependent, | 11 |
| abstract_inverted_index.metalloproteinases | 2 |
| abstract_inverted_index.pathophysiological | 37 |
| abstract_inverted_index.thiazolidinediones | 313 |
| abstract_inverted_index.metalloproteinases, | 304 |
| abstract_inverted_index.thiazolidinediones, | 223 |
| cited_by_percentile_year.max | 97 |
| cited_by_percentile_year.min | 89 |
| corresponding_author_ids | https://openalex.org/A5053343152, https://openalex.org/A5065106283 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 2 |
| corresponding_institution_ids | https://openalex.org/I24354313, https://openalex.org/I4210152303 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.7300000190734863 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.59447136 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |